Literature DB >> 11519485

Acceleration of HIV dementia with methamphetamine and cocaine.

A Nath1, W F Maragos, M J Avison, F A Schmitt, J R Berger.   

Abstract

We report a patient with rapidly accelerating HIV dementia accompanied by seizures and an unusual movement disorder despite highly potent antiretroviral therapy. This clinical constellation was associated with the non-parenteral use of methamphetamine and cocaine. Fractional enhancement time on post contrast magnetic resonance imaging studies revealed a progressive breakdown of the blood brain barrier particularly in the basal ganglia. The movement disorder but not the dementia responded to a combination of dopamine replacement and anticholinergic therapy. While the movement disorder may have been unmasked by concomitant anticonvulsant therapy, we suggest in this instance, that prior drug abuse synergized with HIV to cause a domino effect on cerebral function. Careful attention and analysis to histories of remote non-injecting drug abuse may help substantiate our hypothesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519485     DOI: 10.1080/135502801300069737

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  35 in total

1.  Variable progression of HIV-associated dementia.

Authors:  F H Bouwman; R L Skolasky; D Hes; O A Selnes; J D Glass; T E Nance-Sproson; W Royal; G J Dal Pan; J C McArthur
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

2.  HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia.

Authors:  R K Fujimura; K Goodkin; C K Petito; R Douyon; D J Feaster; M Concha; P Shapshak
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-11-01

3.  Effects of HIV seropositivity and drug abuse on cognitive function.

Authors:  M P Grassi; C Perin; F Clerici; C Zocchetti; M Borella; A Cargnel; A Mangoni
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

4.  Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine.

Authors:  A Nath; N J Haughey; M Jones; C Anderson; J E Bell; J D Geiger
Journal:  Ann Neurol       Date:  2000-02       Impact factor: 10.422

5.  HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement.

Authors:  J E Bell; R P Brettle; A Chiswick; P Simmonds
Journal:  Brain       Date:  1998-11       Impact factor: 13.501

6.  Nigral degeneration in acquired immune deficiency syndrome (AIDS).

Authors:  M G Reyes; F Faraldi; C S Senseng; C Flowers; R Fariello
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

7.  Cerebrospinal fluid dopamine in HIV-1 infection.

Authors:  J R Berger; M Kumar; A Kumar; J B Fernandez; B Levin
Journal:  AIDS       Date:  1994-01       Impact factor: 4.177

8.  Effect of chronic substance abuse on the neuropsychological performance of intravenous drug users with a high prevalence of HIV-1 seropositivity.

Authors:  M Concha; N M Graham; A Muñoz; D Vlahov; W Royal; M Updike; T Nance-Sproson; O A Selnes; J C McArthur
Journal:  Am J Epidemiol       Date:  1992-12-01       Impact factor: 4.897

9.  Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement.

Authors:  M Jones; K Olafson; M R Del Bigio; J Peeling; A Nath
Journal:  J Neuropathol Exp Neurol       Date:  1998-06       Impact factor: 3.685

10.  Exogenous tat protein activates central nervous system-derived endothelial cells.

Authors:  F M Hofman; M M Dohadwala; A D Wright; D R Hinton; S M Walker
Journal:  J Neuroimmunol       Date:  1994-10       Impact factor: 3.478

View more
  94 in total

Review 1.  FIV and neuroAIDS.

Authors:  Howard S Fox; Tom R Phillips
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

2.  Methamphetamine and HIV-1 gp120 effects on lipopolysaccharide stimulated matrix metalloproteinase-9 production by human monocyte-derived macrophages.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Stanley A Schwartz
Journal:  Immunol Invest       Date:  2011-03-22       Impact factor: 3.657

Review 3.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.

Authors:  Linda Chang; Thomas Ernst; Oliver Speck; Charles S Grob
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

5.  Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings.

Authors:  Saurabh Gupta; Chad A Bousman; Gursharan Chana; Mariana Cherner; Robert K Heaton; Reena Deutsch; Ronald J Ellis; Igor Grant; Ian P Everall
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

6.  Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells.

Authors:  Emily S Wires; David Alvarez; Curtis Dobrowolski; Yun Wang; Marisela Morales; Jonathan Karn; Brandon K Harvey
Journal:  J Neurovirol       Date:  2012-05-22       Impact factor: 2.643

Review 7.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 8.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

9.  Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction.

Authors:  L M Moran; R M Booze; K M Webb; C F Mactutus
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

Review 10.  The effects of cocaine on HIV transcription.

Authors:  Mudit Tyagi; Jaime Weber; Michael Bukrinsky; Gary L Simon
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.